NASDAQ · TLX
Telix Pharmaceuticals Limited financials
$11.34−2.41%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q3 '10 Sep 30 | Q2 '10 Jun 30 |
|---|---|---|
| Revenue | $7.1M | $6.3M |
| Gross profit | $1.3M | $1.2M |
| Gross margin | 17.7% | 18.6% |
| Operating income | -$836.0K | -$2.2M |
| Net income | -$1.2M | -$2.6M |
| Net margin | −17.4% | −41.5% |
| Diluted EPS | $-0.01 | $-0.03 |
| EBITDA | $540.0K | -$1.2M |
| Operating cash flow | $112.0K | — |
| Free cash flow | -$282.0K | — |
| Diluted shares | 97.7M | 97.7M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology